| 1 |
樊辛，李路瑶，方琳，等.慢性肾脏病的药物治疗新进展[J].中华肾脏病杂志，2025，41（2）：138-143.
|
| 2 |
Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury[J]. Biomed Res Int, 2014, 2014: 967826.
|
| 3 |
Gyurászová M, Gurecká R, Bábícková J, et al. Oxidative stress in the pathophysiology of kidney disease: implications for noninvasive monitoring and identification of biomarkers[J]. Oxid Med Cell Longev, 2020, 2020: 5478708.
|
| 4 |
Rapa SF, Di Iorio BR, Campiglia P, et al. Inflammation and oxidative stress in chronic kidney disease—potential therapeutic role of minerals, vitamins and plant-derived metabolites[J]. Int J Mol Sci, 2020, 21 (1): 263.
|
| 5 |
孙馨瑜，郭文锋，王亭亭，等.纳米酶在急性肾损伤治疗中的研究进展[J].中华肾脏病杂志，2025，41（5）：403-408.
|
| 6 |
Yu MX, Xu J, Zheng J. Renal clearable luminescent gold nanoparticles: from the bench to the clinic[J]. Angew Chem Int Ed Engl, 2019, 58 (13): 4112-4128.
|
| 7 |
Li S, Dong X, Xu L, et al. Nephroprotective effects of selenium nanoparticles against sodium arsenite-induced damages[J]. Int J Nanomedicine, 2023, 18: 3157-3176.
|
| 8 |
Kong Y, Chen X, Liu F, et al. Ultrasmall polyphenol-NAD+ nanoparticle-mediated renal delivery for mitochondrial repair and anti-inflammatory treatment of AKI-to-CKD progression[J]. Adv Mater, 2024, 36 (30): e2310731.
|
| 9 |
Wang Z, Zhang C. Nanomaterials for targeted therapy of kidney diseases: strategies and advances[J]. Mater Today Bio, 2025, 31: 101534.
|
| 10 |
Tian Z, Liu H, Guo Z, et al. A pH-responsive polymer-CeO2 hybrid to catalytically generate oxidative stress for tumor therapy[J]. Small, 2020, 16 (47): e2004654.
|
| 11 |
Dhall A, Self W. Cerium oxide nanoparticles: a brief review of their synthesis methods and biomedical applications[J]. Antioxidants (Basel), 2018, 7 (8): 97.
|
| 12 |
Chen BH, Stephen Inbaraj B. Various physicochemical and surface properties controlling the bioactivity of cerium oxide nanoparticles[J]. Crit Rev Biotechnol, 2018, 38 (7): 1003-1024.
|
| 13 |
Li M, Liu J, Shi L, et al. Gold nanoparticles-embedded ceria with enhanced antioxidant activities for treating inflammatory bowel disease[J]. Bioact Mater, 2023, 25: 95-106.
|
| 14 |
Liu B, Pan Y, Han Z, et al. Interplay of structural properties and redox behavior in CeO2 nanoparticles: impact on reactivity and bioavailability[J]. Environ Sci Technol, 2025, 59 (9): 4641-4651.
|
| 15 |
Weng Q, Sun H, Fang C, et al. Catalytic activity tunable ceria nanoparticles prevent chemotherapy-induced acute kidney injury without interference with chemotherapeutics[J]. Nat Commun, 2021, 12 (1): 1436.
|
| 16 |
叶倩如，贾丹彤，刘扬，等.大鼠纳米二氧化铈亚慢性暴露后体内分布情况[J].环境卫生学杂志，2020，10（6）：521-526，封3-封4.
|
| 17 |
Roointan A, Xu R, Corrie S, et al. Nanotherapeutics in kidney disease[J]. J Am Soc Nephrol, 2025, 36 (3): 500-518.
|
| 18 |
Abebe A, Kumela K, Belay M, et al. Mortality and predictors of acute kidney injury in adults: a hospital-based prospective observational study[J]. Sci Rep, 2021, 11 (1): 15672.
|
| 19 |
Hoste EAJ, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury[J]. Nat Rev Nephrol, 2018, 14 (10): 607-625.
|
| 20 |
Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes[J]. N Engl J Med, 2014, 371 (1): 58-66.
|
| 21 |
Dennis JM, Witting PK. Protective role for antioxidants in acute kidney disease[J]. Nutrients, 2017, 9 (7): 718.
|
| 22 |
金珍杰，何平. HBV相关性肾炎患者肾组织氧化应激指标SOD、HO-1、8-OHdG的表达及临床意义[J].浙江医学，2023，45（5）：483-486，563.
|
| 23 |
Hong Y, Boiti A, Vallone D, et al. Reactive oxygen species signaling and oxidative stress: transcriptional regulation and evolution[J]. Antioxidants (Basel), 2024, 13 (3): 312.
|
| 24 |
Juan CA, Pérez de la Lastra JM, Plou FJ, et al. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies[J]. Int J Mol Sci, 2021, 22 (9): 4642.
|
| 25 |
Qi R, Yang C. Renal tubular epithelial cells: the neglected mediator of tubulointerstitial fibrosis after injury[J]. Cell Death Dis, 2018, 9 (11): 1126.
|
| 26 |
陈工泽，宋佳，陈文玮，等.静脉淤血超声评分与脓毒症患者急性肾损伤的相关性研究[J/OL].中华危重症医学杂志（电子版），2024，17（6）：465-472.
|
| 27 |
Wang T, Guo W, Lv X, et al. Catalytically self-supplied oxygen to alleviate hypoxia for treatment of acute kidney injury[J]. Adv Funct Mater, 2024, 34 (44): 2404774.
|
| 28 |
Manne ND, Arvapalli R, Nepal N, et al. Cerium oxide nanoparticles attenuate acute kidney injury induced by intra-abdominal infection in Sprague-Dawley rats[J]. J Nanobiotechnology, 2015, 13: 75.
|
| 29 |
Fu X, Li P, Chen X, et al. Ceria nanoparticles: biomedical applications and toxicity[J]. J Zhejiang Univ Sci B, 2024, 25 (5): 361-388.
|
| 30 |
Yu H, Jin F, Liu D, et al. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury[J]. Theranostics, 2020, 10 (5): 2342-2357.
|
| 31 |
Gao X, Wang B, Li J, et al. Catalytic tunable black phosphorus/ceria nanozyme: a versatile oxidation cycle accelerator for alleviating cisplatin-induced acute kidney injury[J]. Adv Healthc Mater, 2023, 12 (30): e2301691.
|
| 32 |
Fu H, Wang Y, Huang B, et al. Tannic acid-cerium nanoenzymes serve as broad-spectrum antioxidants to alleviate acute kidney injury by modulating macrophage polarization, mitophagy and endoplasmic reticulum stress[J]. J Control Release, 2025, 380: 892-909.
|
| 33 |
Lu Y, Neyra JA. How I treat rhabdomyolysis-induced AKI?[J]. Clin J Am Soc Nephrol, 2024, 19 (3): 385-387.
|
| 34 |
Zhang DY, Liu H, Li C, et al. Ceria nanozymes with preferential renal uptake for acute kidney injury alleviation[J]. ACS Appl Mater Interfaces, 2020, 12 (51): 56830-56838.
|
| 35 |
Pu Y, Duan Y, Li W, et al. A cerium single-atom catalyst enables targeted catalytic therapy for acute kidney injury via neutrophil hitchhiking[J]. J Control Release, 2025, 380: 404-416.
|
| 36 |
Zhou L, Tang S, Li F, et al. Ceria nanoparticles prophylactic used for renal ischemia-reperfusion injury treatment by attenuating oxidative stress and inflammatory response[J]. Biomaterials, 2022, 287: 121686.
|
| 37 |
Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms[J]. Nat Rev Nephro, 2022, 18 (9): 545-557.
|
| 38 |
Yang L, Si P, Kuerban T, et al. UHRF1 promotes epithelial-mesenchymal transition mediating renal fibrosis by activating the TGF-β/SMAD signaling pathway[J]. Sci Rep, 2025, 15 (1): 3346.
|
| 39 |
Saifi MA, Peddakkulappagari CS, Ahmad A, et al. Leveraging the pathophysiological alterations of obstructive nephropathy to treat renal fibrosis by cerium oxide nanoparticles[J]. ACS Biomater Sci Eng, 2020, 6 (6): 3563-3573.
|
| 40 |
Adeniyi OE, Adebayo OA, Akinloye O, et al. Combined cerium and zinc oxide nanoparticles induced hepato-renal damage in rats through oxidative stress mediated inflammation[J]. Sci Rep, 2023, 13 (1): 8513.
|
| 41 |
Aslam Saifi M, Hirawat R, Godugu C. Lactoferrin-decorated cerium oxide nanoparticles prevent renal injury and fibrosis[J]. Biol Trace Elem Res, 2023, 201 (4): 1837-1845.
|
| 42 |
Hsu YH, Chiu IJ, Lin YF, et al. Lactoferrin contributes a renoprotective effect in acute kidney injury and early renal fibrosis[J]. Pharmaceutics, 2020, 12 (5): 434.
|
| 43 |
Wang M, Zeng F, Ning F, et al. Ceria nanoparticles ameliorate renal fibrosis by modulating the balance between oxidative phosphorylation and aerobic glycolysis[J]. J Nanobiotechnology, 2022, 20 (1): 3.
|
| 44 |
诸琴红，夏典平，葛芳娣，等.抗氧化和炎症指标在糖尿病肾病患者中的临床意义[J/OL].中华危重症医学杂志（电子版），2024，17（4）：307-311.
|
| 45 |
Tseng CH, Shah KM, Chiu IJ, et al. The role of autophagy in type 2 diabetic kidney disease management[J]. Cells, 2023, 12 (23): 2691.
|
| 46 |
Fan K, Yuan S, Zhou M, et al. Enhanced biohomogeneous composite membrane-encapsulated nanoplatform with podocyte targeting for precise and safe treatment of diabetic nephropathy[J]. ACS Nano, 2023, 17 (18): 18037-18054.
|
| 47 |
Tong Y, Zhang L, Gong R, et al. A ROS-scavenging multifunctional nanoparticle for combinational therapy of diabetic nephropathy[J]. Nanoscale, 2020, 12 (46): 23607-23619.
|
| 48 |
Ho HJ, Shirakawa H. Oxidative stress and mitochondrial dysfunction in chronic kidney disease[J]. Cells, 2023, 12 (1): 88.
|
| 49 |
Wigner P, Grebowski R, Bijak M, et al. The molecular aspect of nephrolithiasis development[J]. Cells, 2021, 10 (8): 1926.
|
| 50 |
Ying X, Chen Y, Hao Z, et al. The significance of reactive oxygen species in the formation of calcium oxalate stones and the protective effects of antioxidants on the kidneys[J]. Front Immunol, 2025, 16: 1540075.
|
| 51 |
Deng J, Yu B, Chang Z, et al. Cerium oxide-based nanozyme suppresses kidney calcium oxalate crystal depositions via reversing hyperoxaluria-induced oxidative stress damage[J]. J Nanobiotechnology, 2022, 20 (1): 516.
|
| 52 |
He Y, Peng E, Ba X, et al. ROS responsive cerium oxide biomimetic nanoparticles alleviates calcium oxalate crystals induced kidney injury via suppressing oxidative stress and M1 macrophage polarization[J]. Small, 2025, 21 (3): e2405417.
|
| 53 |
Majani SS, Singh P, Kumari P, et al. Cerium oxide nanoparticles prepared through Bio-combustion using Ficus carica as effective antioxidant, anticancer and dye degrading agent[J]. Sci Rep, 2025, 15 (1): 30285.
|
| 54 |
Lei L, Wang K. Synergistic combination of an intelligent nanozyme and radiotherapy for treating renal cancer[J]. Int J Nanomedicine, 2024, 19: 699-707.
|